Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 5;19(5):1543–1563. doi: 10.7150/ijbs.77133

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Knockdown of circRBM33 enhances tumor sensitivity to ARSI therapy in PCa. (A) The effects of ARSIs (Enzalutamide and Darolutamide) on circRBM33-depleted 22Rv1 cells in comparison to the negative control. (B) The effects of ARSIs (Enzalutamide and Darolutamide) on circRBM33-silenced C4-2 cells in comparison to the negative control. (C) The workflow shows the subcutaneous tumor mouse model construction based on ARSIs (enzalutamide and darolutamide) oral administration. (D) The comparison of ARSIs' influence on the growth of circRBM33-downregulated tumors.